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EDITORIAL REVIEW
Symptomatic hypotension during hemodialysis
Symptoms during treatment with extracorporeal
hemodialysis are an unpleasant fact of life main-
tained by the artificial kidney. During hemodialysis,
a common clinical pattern is dizziness, malaise,
nausea, and cramps accompanied by a fall in blood
pressure, requiring some form of therapeutic inter-
vention by the nurse or technical team. Such symp-
tomatic hypotension occurs in approximately 25%
of hemodialysis treatments. For some patients,
symptomatic hypotension recurs frequently enough
to make maintenance dialysis a nightmare. This re-
view is an effort to fit into some kind of reasonable
pathophysiologic schema the large body of informa-
tion on symptomatic hypotension.
Vascular volume depletion
"Dry weight" for a given patient is frequently de-
fined as the weight obtained at the conclusion of a
regular dialysis treatment below which the patient
more often than not will become symptomatic and
go into shock. Clinical wisdom quite properly re-
lates symptomatic hypotension not only to the
amount of ultrafiltrate taken during hemodialysis
treatment (net negative fluid balance) but also to the
rate at which the removal occurs. Shear et al dem-
onstrated the rather constant rate of reabsorption of
fluid from the peritoneal space [1-3]. We may rea-
sonably extrapolate from the capillaries of the
splanchnic bed to capillaries throughout the body
and argue that each patient has a finite rate of re-
cruitment of fluid from the extravascular into the
vascular space and that if removal of plasma water
by the artificial kidney exceeds that rate for long
enough, hypovolemic shock with its attendant
symptoms will occur. The logic of shock occurring
when ultrafiltration sufficiently depletes the vascu-
lar volume is undeniable but overly simplistic in the
setting of maintenance dialysis for chronic uremia.
It should be recognized that vascular volume may
be partitioned into intrathoracic and peripheral
"compartments." To date, no studies address
changes in these compartments with artificial kid-
ney treatment. In addition, Bergstrom et al [4, 5],
Schuenemann et al [6], Rouby et al [7], and Rodrigo
et al [8] recently have called attention to the impor-
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tance of osmolar changes occurring during dialysis
therapy. Consider the common circumstance where
1 to 3 liters of plasma water are removed over a 4-
hour period. During the course of that removal,
plasma proteins are concentrated, providing an en-
hanced oncotic force to recruit extravascular fluid
into the vascular space. This force when quan-
titated in terms of milliosmoles per liter would seem
to be trivial at best, as it would provide less than 1/2
mOsm (that is, < 10 mm Hg) driving gradient for
capillary water reabsorption. This, however, is
quite sufficient to unbalance the Starling forces of
the microcirculation in favor of reabsorption of ex-
travascular fluid. Consider further, that the small,
more osmotically active solutes urea and creatinine
move from blood into the dialysis bath. Urea and
creatinine at steady state are presumed to be in dif-
fusion equilibrium with intracellular water. With the
abrupt reduction of the plasma water concentration
of these solutes during dialysis and the lag in equili-
bration across biologic membranes, then an addi-
tional osmotic driving gradient for cell uptake of
water would occur, leaving the extracellular space
to be refilled from the already diminished intra-
cellular space. For a given ultrafiltration rate, the
magnitude of this volume depletion would clearly
be a direct function of the rate of fall in plasma urea
concentration with dialysis. "High efficiency"
dialyzers, especially when used in the clinical set-
ting of a high plasma urea nitrogen, would then put
the patient at greater risk for symptomatic hypoten-
sion than would less efficient (smaller area) dialy-
zers or peritoneal dialysis, where the urea clearance
rate is less [9—13].' Further, dialyzers with large
'Dialyzers with a greater than 1.0 m2 of membrane area and with
a urea clearance at 200 mI/mm blood flow rate of 150 mI/mm
(range 150 to 180 mI/mm) are considered to be high efficiency
when compared with more standard equipment where urea clear-
ances of 120 mI/mm are common.
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surface areas offer the potential for shorter treat-
ment periods, and hence, the fluid removal required
to maintain the patient dry" must be accom-
plished in this shorter treatment time, accentuating
the problem of symptomatic hypotension. These
pathophysiologic speculations have recently been
tested and found to be valid [7, 14].
From this pathophysiologic schema, we may then
examine the observation by Bergstrom and others
that if ultrafiltration is conducted separately in time
from diffusional solute loss, that symptomatic hypo-
tension is less frequent. By separating ultrafiltration
with its resulting increase in oncotic force from dif-
fusional urea removal, we may speculate that there
is but a single force depleting the vascular volume
(ultrafiltration) and that this is partially offset by the
enhanced oncotic force recruiting extravascular
volume. Note that all empirical therapies offered for
symptomatic hypotension (hypertonic mannitol,
isotonic and hypertonic saline and plasminate) pro-
vide an extracellular solute particle with osmotic
or oncotic capability to recruit vascular volume.
The data obtained on cardiac output and periph-
eral vascular resistance of uremic patients under-
going hemodialysis bear comment. The studies in
humans by Wehle et al [15], Hampl et al [16], and
Chen et al [17] using both invasive and noninvasive
methods and the studies in dogs by Keshaviah et al
[14] showed a failure of peripheral resistance to in-
crease appropriately with fluid removal during con-
ventional hemodialysis. In addition, heart rate (and
cardiac output) failed to increase, as noted by oth-
ers using noninvasive techniques to assess these
autonomic nervous system compensatory mecha-
nisms. Compensatory peripheral vasoconstriction
with fluid removal was better maintained with both
sequential filtration and dialysis [15] and hemo-
filtration [16] than it was for hemodialysis. Al-
though these findings add a further level of under-
standing to the pathophysiologic events leading to
symptomatic hypotension, the underlying cause for
the differences noted remains obscure. We may
speculate that the functional "lesion" identified is
the result of an acute vasculopathy or autonomic
neuropathy mediated by an osmotic fluid shift that
results in failure of the afferent and efferent resis-
tances of the microvasculature to constrict appro-
priately when fluid is removed from the vascular
space.
Phvsicoche,nical toxicity
The work of Graefe et al [12] and Novello et al
[18] in humans and that of Keshaviah et al [14] and
Kirkendol et al [19] in animals suggest the impor-
tance of acetate as an etiologic agent for sympto-
matic hypotension in certain instances. The rate at
which acetate may be metabolically disposed of
varies from patient to patient. Symptomatic hypo-
tension occurs in those where the rate of acetate
uptake from the treatment exceeds its rate of me-
tabolism in the tissues and a significant level of ace-
tate develops in the blood. Kishimoto et al [20],
studying 27 patients treated with an acetate bath,
showed that serum acetate concentrations in those
with symptomatic hypotension (56% of 102 dial-
yses) had an average serum acetate concentration
of 4.5 1.2 mmoles/liter as compared with a con-
centration of 1.4 0.5 mmoles/liter (P < 0.005) foi
those who were free of this complication. High effi-
ciency dialysis again predisposes toward higher
plasma acetate concentrations. The precise mecha-
nism for acetate's action is still unclear; that is, is it
cardiotoxic, or is the toxicity primarily at the micro-
circulatory level with venular pooling secondarily
compromising cardiac output? Or both?
Autono,nic neuropathy
Classical compensatory cardiovascular mecha-
nisms protect us from changes in vascular volume.
Carotid, aortic, and cardiopulmonary baroreceptors
sense a depletion in arterial vascular volume. In
compensation, an increase in both cardiac output
and peripheral vascular resistance occurs in an ef-
fort to hold blood pressure stable. Autonomic in-
sufficiency has been noted in the patient with end-
stage renal failure by several groups [2 1—27]. Lilley,
Golden, and Stone implicate the carotid and aortic
body baroreceptor reflex arc as being defective in a
subset of the uremic population [26]. Their data sug-
gest a defect that lies in the afferent limb and may be
anywhere along its path; that is, the baroreceptors
themselves, the baroreceptor nerve, or its central
connections in the medulla. Typical clinical findings
in this group were hypertension, lability of blood
pressure as clinically manifest by the usual pres-
ence of symptomatic hypotension when fluid was
removed during routine clinical hemodialysis, and a
significantly higher plasma dopamine-/3-hydrox-
ylase (DBH) activity. Total peripheral resistance in
these patients was not measured, but it has been
shown by others to be high when corrected for the
low hematocrit typically present with chronic ure-
mia [28, 29]. Patients demonstrating baroreceptor
reflex arc dysfunction show findings similar to ani-
mals in which surgical section of the afferent nerve
from the baroreceptors has been performed [30—33].
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Fig. 1. Time course in 11 patients for the improvement in symp-
toms requiring treatment. Each bar represents the mean value
for the number of therapeutic interventions recorded by the
nurse for ten treatments. The number of interventions noted for
the first and last ten hemofiltration treatments is significantly dif-
ferent from the first and last ten hemodialysis treatments (P <
0.05). The first ten treatments on return to hemodialysis after
hemofiltration also show this significant improvement. Weight
loss during hemofiltration is significantly greater than it is with
hemodialysis (P < 0.01).
These animals are hypertensive, have a high total
peripheral resistance resulting from unopposed
sympathetic nervous system activity, and lability of
blood pressure in response to sodium and volume
loading.
DBH is a presynaptic enzyme that catalyzes the
last step in the series of reactions leading to the syn-
thesis of norepinephrine. It is secreted into the
plasma on a mole-for-mole basis with norepineph-
rine. DBH, when contrasted with norepinephrine,
is not readily degraded biochemically or eliminated
at all from the plasma by reuptake by the nerve end-
ing or loss in the urine. Hence, DBH has a sub-
stantially longer half life in the plasma than does
norepinephrine [31, 34, 35]. It is considered by
many to reflect a longer-term (days) level of activity
of the sympathetic nervous system more closely
than does plasma norepinephrine concentration,
which reflects the more acute (minute to minute)
peak and valley swings in activity. Elevation of
plasma DBH activity then may be considered as ad-
ditional supporting evidence for an excess of sym-
pathetic nervous system "tone."
I have studied a small group of patients with end-
stage renal disease undergoing hemofiltration. They
were selected only because they had significant hy-
pertension [36]. In a crossover protocol where he-
mofiltration was compared with bracketing control
observations, half responded to hemofiltration with
a significant reduction in mean arterial pressure af-
ter 3 months time on treatment. Changes of the
mean arterial pressure to sodium and volume load-
ing (that is, the changes in mean arterial pressure
between that measured at the end of one treatment
and prior to initiating the next [zMAP]) were taken
as an index of blood pressure lability. Those who
showed a reduction in mean arterial pressure also
showed both a reduction of LMAP and plasma
DBH activity [36, 37]. Furthermore, a significant re-
duction in the frequency of symptomatic hypoten-
sion during treatment was noted with hemofiltration
[3 8—40]. With return to hemodialysis, mean arterial
pressure, zMAP, and plasma DBH activity re-
turned to control values within 3 months, as did the
incidence of symptomatic hypotension. The find-
ings of decreased blood pressure and blood pres-
sure lability suggest improved baroreceptor reflex
arc function as a result of hemofiltration.2 Normal-
ization of blood pressure and a reduced number of
episodes of symptomatic hypotension have sub-
sequently been noted by other groups [43, 44].
Figure 1 plots the number of therapeutic inter-
ventions per treatment with the artificial kidney for
hemofiltration and hemodialysis in our study.
Weight reduction per treatment is also plotted. A
significant reduction in the need for therapy is noted
with hemofiltration. The time course for the reduc-
tion in number of episodes of symptomatic hypoten-
sion, when compared with that for the reduction in
mean arterial pressure, and L.MAP showed that im-
provement in symptomatic hypotension occurs with
the very first ten hemofiltration treatments under-
taken, whereas the other findings were manifest on-
2The complex problem of baroreceptor function and high blood
pressure has received a lot of attention since 1923 when Hering
first discovered the carotid sinus reflex and postulated that a de-
rangement of this reflex might cause hypertension. I do not in-
tend to offer a full review of this information. Suffice it to say that
present thinking {41] indicates that a resetting of the level of the
"servo point," around which the reflex modulates changes in
blood pressure, occurs at a higher level in nonuremic patients
with hypertension. Whether hypertension or "resetting" is the
first event is not clear. Further, it is not clear whether reflex sen-
sitivity (gain) is blunted by moderate hypertension. Last, studies
to determine reflex resetting and altered sensitivity in patients
with renal failure and hypertension are few [23—27]. They in-
dicate, primarily, a reduction in sensitivity of the mechanisms
involving baroreceptor pulse interval regulation. In addition, al-
though data from Kersh et al [25] suggest a normal end-organ
responsiveness to catecholamine, Romoffet al have data to sug-
gest end-organ unresponsiveness [42].
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ly in the last 4 to 6 weeks of the 3-month study peri-
od on hemofiltration [39]. This occurred in spite of
greater weight loss during treatment with hemo-
filtration than with hemodialysis. Furthermore, on
return to hemodialysis, the lowered incidence of
symptomatic hypotension persisted for the first ten
treatments, but it rose to prehemofiltration control
levels in the last 4 to 6 weeks of the concluding con-
trol period (see Fig. 1). The different time course
noted for the reduction in symptomatic hypoten-
sion, as opposed to reduction in MAP and IMAP,
raises several points of interest. First, it indicates
that there are at least two pathophysiologic mecha-
nisms underlying the reduction in symptomatic
hypotension noted with hemofiltration. One, be-
cause of its abrupt onset, may well relate to a tech-
nical difference between hemofiltration and hemo-
dialysis (for example, the less efficient removal of
urea and creatinine and the presentation of more
acetate with hemofiltration than for hemodialysis or
the use of a different [noncellulosic] membrane3).
The other, with its slow course of onset that persists
on return to hemodialysis, suggests a biological
rather than a technical event (for example, im-
proved removal of a slowly accumulating middle
molecule that inhibits one or another component of
the afferent limb of the baroreceptor reflex arc with
subsequent restoration towards normal of the he-
modynamic responses to vascular volume reduc-
tion). Of interest is a preliminary report from Shal-
don et al [45] in which changes in osmolality and in
posttreatment acetate concentrations were com-
parable during hemofiltration and hemodialysis in a
small group of patients who showed the prompt and
significant reduction in symptomatic hypotension
noted in Fig. I. If acetate toxicity and alterations in
osmolar and oncotic relationships are excluded in
the explanation of the early component of improve-
ment in symptomatic hypotension, more emphasis
is placed on differences in the membrane used.
Membrane toxicity
Cellulosic membrane clearly triggers surface sen-
sitive proteins discharging the complement cas-
cade. This, in turn, relates temporally to the pulmo-
nary sequestration of leukocytes early in the course
of cellulosic hemodialysis [46—51]. Some feel this
leukocyte sequestration may underly the fall in arte-
rial partial pressure of oxygen (PaO2) noted with he-
3Two membranes have been most widely used for hemo-
filtration: the Rhone Poulenc RP-6 polyachrilonitrile membrane
and the Amicon XP-50 anisotropic polysulfone membrane.
Table 1. Potential causes for symptomatic hypotension
during dialysis
1. Osmotic/oncotic derangements of vascular volume
2. Uremic autonomic neuropathy
3. Toxicity of acetate
4. Toxicity of cellulosic membrane
5. Other
modialysis [50, 51]. The dissociation between leu-
kocyte sequestration and a reductiOn in PaO2 casts
doubt, however, on this as the etiologic mechanism
[52]. Amicon XM-50 membrane has been contrast-
ed closely with the regenerated cellulose acetate
membrane from Dow and found not to cause such
leukocyte sequestration or to perturb inherent leu-
kocyte function such as random mobility, phagocy-
tosing ability, or response to a chemotactic stimulus,
unlike the Dow membrane [49]. The closely related
XP-50 membrane from Amicon now commonly
being used for hemofiltration also does not cause
hemodialysis leukopenia (Henderson, unpublished
observations), nor does AN-69 polyachrilonitrile
membrane from Rhone Poulenc, although the latter
does trigger complement [54]. To date, no prospec-
tive studies have been reported to test the hypothe-
sis that cellulosic membrane toxicity may be re-
sponsible for some of the symptomatic hypotension
noted during hemodialysis.
What may we conclude from all of this? First,
symptomatic hypotension is multifactorial. Table
1 lists the significant factors derived from my per-
ception of the literature. Note that items 4 and 5
are purely speculative. Second, different patients
may well show different patterns of clinical re-
sponse to treatment, depending on which factor
or factors may predominate at the time of treat-
ment. This might reconcile some of the conflicting
information in the literature, for example, the find-
ings of Bergstrom et al with others studying sequen-
tial ultrafiltration and hemodialysis. Third, any
study undertaken to identify cause and effect rela-
tionships between symptoms and treatment method
must address all of these potential variables. Our
understanding of symptomatic hypotension is of ut-
most importance for the patient, as rational therapy
can only be offered after the pathophysiologic
mechanisms for its occurrence are understood.
LEE W. HENDERSON
La Jolla, California
Reprint requests to Dr. L. W. Henderson, Department of
Medicine, Renal Division, Veterans Administration Hospital,
3350 La Jolla Village Drive, La Jolla, California 9216!, USA
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